REG-Syncona Limited: Autolus files for proposed IPO in the US

SynconaAnnouncement

08/05/2018 07:05

Syncona Limited

Autolus files for proposed initial public offering in the United States

8 May 2018

Syncona Ltd, a leading healthcare company focused on investing in and building
global leaders in life science, today notes that its portfolio company Autolus
Therapeutics Limited (to be reorganised as Autolus Therapeutics plc)
(“Autolus”) has filed a registration statement on Form F-1
(“Registration Statement”) with the U.S. Securities and Exchange
Commission (the “SEC”) relating to a proposed initial public offering
(“IPO”) in the United States of its American Depositary Shares
(“ADSs”), each representing one ordinary share. All ADSs to be sold in the
proposed IPO will be offered by Autolus. Autolus intends to apply to list its
ADSs on the Nasdaq Global Market under the ticker symbol “AUTL”. The
number of ADSs to be sold and the pricing terms for the proposed IPO have not
yet been determined.

The Registration Statement relating to the ADSs has been filed with the SEC
but has not yet become effective. The ADSs may not be sold nor may offers to
buy be accepted prior to the time the Registration Statement becomes
effective.

The Registration Statement can be accessed through the SEC’s EDGAR
Database.  Syncona notes that the Registration Statement contains further
information relating to Autolus, and further notes that the information
includes previously unpublished information relating to Autolus’ current
clinical trials.

This announcement does not constitute an offer to sell or the solicitation of
an offer to buy securities, and shall not constitute an offer, solicitation or
sale in any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
that jurisdiction.

The securities referred to in this announcement are to be offered only by
means of a prospectus. When available, copies of the preliminary prospectus
can be obtained from either of the joint book-running managers for the
offering, Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New
York, NY 10282, or by telephone at +1 866 471 2526 or by email at
prospectusgroup-ny@ny.email.gs.com; or Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY
10022, or by telephone at + 1 877 547 6340, or by email at
Prospectus_Department@Jefferies.com.

 ENDS 

Enquiries

Syncona Ltd
Siobhan Weaver
Tel: +44 (0) 20 7611 2031

Tulchan Communications
Martin Robinson
Lisa Jarrett-Kerr
Tel: +44 (0) 207 353 4200

Forward-looking statements – this announcement contains certain
forward-looking statements with respect to the portfolio of investments of
Syncona Ltd. These statements and forecasts involve risk and uncertainty
because they relate to events and depend upon circumstances that may or may
not occur in the future. There are a number of factors that could cause actual
results or developments to differ materially from those expressed or implied
by these forward-looking statements and forecasts. Nothing in this
announcement should be construed as a profit forecast.

About Syncona

Syncona is a leading FTSE250 healthcare company focused on investing in and
building global leaders in life science. Our vision is to deliver
transformational treatments to patients in truly innovative areas of
healthcare while generating superior returns for shareholders. Our current
investment portfolio consists of seven high quality companies in life science
and a leading range of fund investments.

We seek to partner with the best, brightest and most ambitious minds in
science to build globally competitive businesses. We are established leaders
in gene therapy, cell therapy and advanced diagnostics, and focus on
delivering dramatic efficacy for patients in areas of high unmet need.

Our fund investments represent a productively deployed evergreen funding base
which enables us to take a long term approach to investing in life sciences as
we target the best new opportunities and support our existing portfolio
companies to grow and succeed.

Syncona is aligned with two of the premium charitable funders in UK science,
the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both
of which are significant shareholders in our business.  We make a donation of
0.3% of Net Asset Value to a range of charities each year.

About Autolus

Autolus is a biopharmaceutical company developing next-generation programmed T
cell therapies for the treatment of cancer.



Copyright (c) 2018 PR Newswire Association,LLC. All Rights Reserved